Follow Doximity to never miss an important update.
The law firm Bernstein Litowitz Berger & Grossmann filed a lawsuit in California on behalf of investors who bought Doximity stock. The suit alleges that the company and some of its executives violated federal securities laws, which usually involves claims that a company made misleading statements about its business or financial health.
Lawsuits like this are common when a stock has seen a sharp drop, as Doximity has this year. While they often take years to resolve and are frequently dismissed, they can be a distraction for management and sometimes lead to expensive settlements. We will watch for whether the court allows the case to move forward or if the specific allegations point to a deeper problem with how the company reports its numbers.
Source: Business Wire
Freedom Capital Markets lowered its rating on the company from buy to hold. This change comes as the stock has faced a difficult year, though the average price target among all analysts remains about 15 percent higher than the current price.
For a business that relies on pharmaceutical companies shifting their marketing budgets to its digital platform, a rating downgrade often reflects a more cautious view on how quickly that shift is happening. While the company maintains a strong grip on physician attention, this move suggests some analysts see less room for the stock to grow in the near term.
Wells Fargo downgraded the company to its lowest rating, underweight. This is a signal from the firm's analysts that they expect the stock to perform worse than the average company in the market over the coming months.
While the company recently reported growth in its AI tools, this downgrade suggests a major firm is becoming more cautious about its path ahead. For a business that relies on pharmaceutical companies shifting their marketing budgets to its digital platform, a downgrade like this often reflects concerns about how quickly that shift is happening or whether the current stock price has already accounted for future growth.
Doximity reported revenue of about 157 million dollars for the quarter, which is 7 percent higher than the same time last year. While its earnings of 29 cents per share were slightly lower than the 30 cents analysts expected, the business remains highly profitable with a 48 percent margin on adjusted EBITDA. This is a measure that shows how much cash a company earns from its core operations before accounting for things like taxes and interest.
The real highlight is how much doctors are using the platform. The number of active prescribers using its workflow tools rose more than 30 percent, and queries for its AI search tool grew 25 percent from the previous quarter. For a company that makes money by selling digital ads to pharmaceutical firms, keeping doctors logged in and using these tools is the most important part of the business. As long as doctor engagement stays high, the shift of marketing budgets from physical sales reps to Doximity's digital platform should continue.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company reports its first-quarter results after the closing bell today. Analysts are looking for earnings of about 30 cents per share on 150 million dollars in revenue. Beyond the top-line numbers, we are watching for updates on how many doctors are using its clinical tools and whether pharmaceutical companies are continuing to shift their marketing budgets to the platform. These are the core drivers of the business's high-margin growth.
Management has lost its long streak of clearing its own bars, with two straight misses suggesting the business is becoming harder to forecast as growth slows.
| Expectation | |
|---|---|
| EPS | $0.34 |
| Revenue | $171M |